HR-positive
HER2-negative

IRB# 6256
ISPY-2: Neoadjuvant and Personalized Adaptive Novel Agents

IRB# 21243
Neoadjuvant Abemaciclib and Niraparib (PANNTHR)

IRB# 22191
Keynote-756: Pembrolizumab/Placebo in combo with neoadjuvant chemotherapy & Adjuvant Endocrine Therapy

HER2-positive

IRB# 6256
ISPY-2: Neoadjuvant and Personalized Adaptive Novel Agents

Triple Negative

IRB# 6256
ISPY-2: Neoadjuvant and Personalized Adaptive Novel Agents

http://www.ohsu.edu/research/rda/so/knight.php

Key

- Open for Enrollment
- In Development
- Enrollment on Hold
BREAST CANCER

METASTATIC THERAPY

1L

IRB#22225
OP-1250-001: A Dose Escalation/Expansion study of OP-1250

IRB#22225
SERENA-4: AZD9833 with palbociclib vs. anastrozole with palbociclib

IRB#20440
CT7001-001: CT7001 Alone and in Combination with Anti-Cancer Treatments

2L

IRB#22765 DESTINY-Breast08: Phase 1b Study of T-DXd Combinations in HER2-low a/mBC

>2L

IRB#22765 DESTINY-Breast08: Phase 1b Study of T-DXd Combinations in HER2-low a/mBC

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php
Breast Cancer

Metastatic Therapy

HER2-positive

1L
- No trials currently available
- EA1183: FDG-PET/CT (IRB#21441)
- EA1183: FDG-PET/CT (IRB#21441)
- EA1183: FDG-PET/CT (IRB#21441)
- S1501: Carvediol in Preventing Cardiac Toxicity (IRB#19078)
- S1501: Carvediol in Preventing Cardiac Toxicity (IRB#19078)
- S1501: Carvediol in Preventing Cardiac Toxicity (IRB#19078)

2L
- IRB#19830: TDM1 +/- Palbociclib
- EA1183: FDG-PET/CT (IRB#21441)
- EA1183: FDG-PET/CT (IRB#21441)
- S1501: Carvediol in Preventing Cardiac Toxicity (IRB#19078)
- S1501: Carvediol in Preventing Cardiac Toxicity (IRB#19078)
- S1501: Carvediol in Preventing Cardiac Toxicity (IRB#19078)

>2L
- IRB#19078: S1501: Carvediol in Preventing Cardiac Toxicity

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php
BREAST CANCER

METASTATIC THERAPY

1L
AMTEC: Olaparib + Durvalumab
IRB#18504

2L
AMTEC: Olaparib + Durvalumab
IRB#18504

>2L
AMTEC: Olaparib + Durvalumab
IRB#18504

IRB#17887
SGNLVA-001: (Part F) A Safety Study of SGN-LIV1a

IRB 22765 DESTINY-Breast08: Phase 1b Study of T-DXd Combinations in HER2-low a/mBC

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

12 Nov 2021
### CROSS-DISEASE TRIALS

<table>
<thead>
<tr>
<th>Trial ID</th>
<th>Description</th>
</tr>
</thead>
</table>
| IRB#15588 (SMMART-PRIME) | • Heavily Pre-treated  
• HR+HER2-; HER2+; TNBC |
| IRB#20679 (SMMART-ACT) | • HR+HER2-; HER2+; TNBC  
• Pre-screen (molecular target) |
| IRB#19904 (NEO-RAY, Nuc Med) | • Heavily Pre-treated  
• Pre-screen required |
| IRB#19992 (EAY131, MATCH) | • Pre-screen (molecular target) |
| IRB#18084 (S1609, DART) | • Pre-screen (rare molecular target) |
| IRB#19489 (Lutathera IIT) | • Targeting Metastatic Breast Cancer and Breast Cancer Stem Cells with Lutathera |
| IRB#16676 (BLU-667, Phase 1) | • Advanced solid tumor with oncogenic RET fusion (expected to close soon) |
| IRB#18164 (Loxo RET, Phase 1) | • RET fusion-positive |

[http://www.ohsu.edu/research/rda/so/knight.php](http://www.ohsu.edu/research/rda/so/knight.php)
### CROSS-DISEASE TRIALS

#### Continued

<table>
<thead>
<tr>
<th>IRB#</th>
<th>Trial Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>21349</td>
<td><strong>TNBC</strong>: Previously treated (cytotoxic or targeted anticancer agents) in the metastatic setting.</td>
</tr>
<tr>
<td>MORAB-202 (Phase 1)</td>
<td></td>
</tr>
<tr>
<td>21766</td>
<td><strong>Patients must have progressed on at least two lines of approved therapy for their histological subtype</strong></td>
</tr>
<tr>
<td>GEN001 (Phase 1)</td>
<td></td>
</tr>
<tr>
<td>21508</td>
<td><strong>TNBC</strong> with no alternative effective standard therapy</td>
</tr>
<tr>
<td>ORIC-101 (Phase 1)</td>
<td></td>
</tr>
<tr>
<td>21548</td>
<td><strong>TNBC</strong> relapsed/refractory to at least one line of systemic chemotherapy in the metastatic setting or intolerant of existing therapy(ies).</td>
</tr>
<tr>
<td>AMG 650 (Phase 1)</td>
<td></td>
</tr>
<tr>
<td>21819</td>
<td><strong>Phase 1B</strong>: documented activating gene mutations in BRAF (BRAF V600 mutation or activating atypical non-V600 aberrations), KRAS, NRAS, or HRAS</td>
</tr>
<tr>
<td>ASTX029 (Phase 1)</td>
<td></td>
</tr>
</tbody>
</table>

1 To inquire about Phase 1 trial open slots please contact stadnik@ohsu.edu.

http://www.ohsu.edu/research/rda/so/knight.php